BR112022019611A2 - Compostos, composições farmacêuticas e métodos para preparar compostos e seu uso - Google Patents

Compostos, composições farmacêuticas e métodos para preparar compostos e seu uso

Info

Publication number
BR112022019611A2
BR112022019611A2 BR112022019611A BR112022019611A BR112022019611A2 BR 112022019611 A2 BR112022019611 A2 BR 112022019611A2 BR 112022019611 A BR112022019611 A BR 112022019611A BR 112022019611 A BR112022019611 A BR 112022019611A BR 112022019611 A2 BR112022019611 A2 BR 112022019611A2
Authority
BR
Brazil
Prior art keywords
compounds
methods
pharmaceutical compositions
preparing
pharmaceutically acceptable
Prior art date
Application number
BR112022019611A
Other languages
English (en)
Inventor
Szychowski Janek
Liu Bingcan
Dietrich Evelyne
Vallée Frédéric
Perryman Alexander
TRUCHON Jean-François
Papp Robert
Beaulieu Patrick
Original Assignee
Repare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repare Therapeutics Inc filed Critical Repare Therapeutics Inc
Publication of BR112022019611A2 publication Critical patent/BR112022019611A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPOSTOS, COMPOSIÇÕES FARMACÊUTICAS E MÉTODOS PARA PREPARAR COMPOSTOS E SEU USO. A presente invenção refere-se a compostos e sais farmaceuticamente aceitáveis dos mesmos que podem ser usados no tratamento de indivíduos em necessidade dos mesmos. Os compostos divulgados neste documento podem ser inibidores de tirosina e inibidor de cdc2 específica de treonina cinase (Myt1). Também são divulgadas composições farmacêuticas contendo os compostos ou sais farmaceuticamente aceitáveis dos mesmos e métodos de sua preparação e uso.
BR112022019611A 2020-04-01 2021-04-01 Compostos, composições farmacêuticas e métodos para preparar compostos e seu uso BR112022019611A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003745P 2020-04-01 2020-04-01
PCT/CA2021/050443 WO2021195781A1 (en) 2020-04-01 2021-04-01 Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use

Publications (1)

Publication Number Publication Date
BR112022019611A2 true BR112022019611A2 (pt) 2022-11-29

Family

ID=77927736

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019611A BR112022019611A2 (pt) 2020-04-01 2021-04-01 Compostos, composições farmacêuticas e métodos para preparar compostos e seu uso

Country Status (14)

Country Link
US (1) US20230151014A1 (pt)
EP (1) EP4126879A4 (pt)
JP (1) JP2023521633A (pt)
KR (1) KR20230011279A (pt)
CN (1) CN115916783A (pt)
AU (1) AU2021250744A1 (pt)
BR (1) BR112022019611A2 (pt)
CA (1) CA3177200A1 (pt)
CO (1) CO2022015638A2 (pt)
CR (1) CR20220558A (pt)
EC (1) ECSP22083904A (pt)
IL (1) IL296934A (pt)
MX (1) MX2022012178A (pt)
WO (1) WO2021195781A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023519430A (ja) * 2020-04-01 2023-05-10 リペア セラピューティクス インコーポレイテッド Ｍｙｔ１阻害剤の使用方法
US20240034736A1 (en) * 2020-09-30 2024-02-01 Fl2022-001, Inc. Hsd17b13 inhibitors and uses thereof
CA3214900A1 (en) * 2021-04-07 2022-10-13 Jimmy FOURTOUNIS Carboxamide pyrolopyrazine and pyridine compounds useful as inhibitors of myt1 and use thereof in the treatment of cancer
WO2023155892A1 (en) * 2022-02-18 2023-08-24 Insilico Medicine Ip Limited Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
WO2023155870A1 (en) * 2022-02-18 2023-08-24 Insilico Medicine Ip Limited Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
WO2023174329A1 (en) * 2022-03-15 2023-09-21 Insilico Medicine Ip Limited Heteroaromatic compounds as pkmyt1 inhibitors and use thereof
WO2023198199A1 (zh) * 2022-04-15 2023-10-19 先声再明医药有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂
WO2023220831A1 (en) * 2022-05-18 2023-11-23 Repare Therapeutics Inc. Heteroarenes, pharmaceutical compositions containing the same, and methods of using the same
WO2023249563A1 (en) * 2022-06-23 2023-12-28 Engine Biosciences Pte. Ltd. Compounds and method for pkmyt1 inhibition
WO2024012409A1 (zh) * 2022-07-12 2024-01-18 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
WO2024041440A1 (en) * 2022-08-24 2024-02-29 Danatlas Pharmaceuticals Co., Ltd. Tricyclic heterocyclic derivatives, compositions and uses thereof
WO2024048687A1 (ja) * 2022-08-31 2024-03-07 中外製薬株式会社 Ｍｙｔ１阻害剤と化学療法剤を併用する、ｒｂ１の機能低下が生じている患者のがんの治療剤及び治療方法
WO2024061343A1 (zh) * 2022-09-23 2024-03-28 先声再明医药有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂及其应用
WO2024104282A1 (zh) * 2022-11-14 2024-05-23 捷思英达控股有限公司 一种1H-吡咯并[2,3-b]吡啶衍生物、其制备方法及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1137415A4 (en) * 1998-12-07 2002-03-20 Smithkline Beecham Corp MYT1 KINASE INHIBITORS
CO5261594A1 (es) * 2000-03-02 2003-03-31 Smithkline Beecham Corp Inhibidores de myt1 cinasa
WO2015073528A1 (en) * 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
AU2015318233B2 (en) * 2014-09-15 2020-03-12 Plexxikon Inc. Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
MX2022012178A (es) 2022-12-08
EP4126879A4 (en) 2024-04-10
JP2023521633A (ja) 2023-05-25
EP4126879A1 (en) 2023-02-08
IL296934A (en) 2022-12-01
AU2021250744A1 (en) 2022-11-17
KR20230011279A (ko) 2023-01-20
CA3177200A1 (en) 2021-10-07
CR20220558A (es) 2022-12-12
US20230151014A1 (en) 2023-05-18
ECSP22083904A (es) 2022-11-30
WO2021195781A1 (en) 2021-10-07
CN115916783A (zh) 2023-04-04
CO2022015638A2 (es) 2022-11-18

Similar Documents

Publication Publication Date Title
BR112022019611A2 (pt) Compostos, composições farmacêuticas e métodos para preparar compostos e seu uso
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
BR112021026395A2 (pt) Compostos de 2,3-di-hidroquinazolina como inibidores de nav1.8
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
BR112022007612A2 (pt) Inibidores de raf quinases
BR112022007867A2 (pt) Degradadores de pequena molécula de helios e métodos de uso
BRPI0507065B8 (pt) derivados de quinolina, composição que os compreende, seu processo de preparação e seu uso como inibidores micobacterianos
BRPI0410563A (pt) derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase
BR112023009531A2 (pt) Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos
BR112018068565A2 (pt) combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
BR112018008397A2 (pt) derivados de di-hidroimidazopirazinona úteis no tratamento do câncer
BR112022002532A2 (pt) Compostos heterocíclicos como inibidores de quinase
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
BR112021023824A2 (pt) Inibidor de proteína quinase dependente de dna
PL378064A1 (pl) Pirymidyny i triazyny hamujące replikację wirusa HIV
BRPI0817843B8 (pt) inibidores da quinase c-fms, composição farmacêutica que os compreende e processo para a fabricação da dita composição
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
BRPI0511999A (pt) compostos como antagonistas de ccr5
BR112019024322A2 (pt) Compostos e composições terapêuticos e métodos de uso dos mesmos
BR112017007239A2 (pt) inibidor da aurora a cinase, seus usos, e composição farmacêutica".
BR112023003948A2 (pt) Compostos de antagonista de quinolina cgas
BR112022022669A2 (pt) Inibidores de nek7 quinase
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
BRPI0417609B8 (pt) derivados de 3-ciano-quinolina com atividade antiproliferativa, seu processo de preparação e uso e composição farmacêutica que os compreende